04/20/2021 11:48 AM
Clarín.com
World
Updated 04/20/2021 12:01 PM
The European Medicines Agency (EMA) recognized "possible" cause-and-effect links between the Johnson & Johnson vaccine and the
"very rare" cases of cerebral thrombosis
that occurred in the United States.
This was stated in a statement from the European body, where it is specified, however, that the benefits outweigh the risks.
He specified, however, that these episodes should be included as
"very rare side effects"
of the drug.
The EMA shows that in the administration of Janssen, the Johnson & Johnson vaccine,
"the benefits outweigh the risks"
, according to the conclusions at the end of the review of the serum, after rare cases of cerebral thrombosis in the United States.
The EMA recommended the use of the Johnson & Johnson vaccine despite the "rare cases" of clots.
Photo: DPA
All rare events of cerebral thrombosis "
occurred in people under 60 years of age
within three weeks of vaccination" with Johnson & Johnson serum, "the majority in women"
"Based on the currently available evidence, the specific risk factors were not confirmed," the EMA added.
Six cases under study
Last Wednesday the pharmaceutical company announced that it was delaying the launch of its vaccine against COVID-19 in Europe, after the stoppage in the United States due to
six cases of thrombotic events in people vaccinated
with its injection, after administering more than 6.8 million dose of the vaccine.
Hours later, the EMA pointed out that its safety committee (PRAC) was also reviewing cases of the six thrombi that occurred in the United States after the use of Janssen's COVID-19 vaccine.
The reported type of blood clot, cerebral venous sinus thrombosis (CVST), occurred in most cases in combination with low levels of platelets in the blood (thrombocytopenia).
Cases
very similar to those that occurred with the AstraZeneca vaccine
, which are still under study since the EMA, although two weeks ago, after a preliminary study, it recommended including these adverse events in the list of "very rare" side effects of the vaccine .
The
COVID-19 Janssen vaccine is a vaccine to prevent
coronavirus
disease
2019 (COVID-19) in people over 18 years of age.
It is made up of another virus (from the adenovirus family) that has been modified to contain the gene to produce a protein found in SARS-CoV-2.
It stands out from the rest because it is administered in a single injection, although its effectiveness is lower compared to this, 67%.
It was granted conditional marketing authorization from the European Commission on March 11, 2021.
Source: agencies
Look also
US frees access to coronavirus vaccine without age limits for all
Pfizer announced delivery of 100 million more doses of COVID vaccines to the European Union
